These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18535026)

  • 21. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Menarche increases relapse risk in pediatric multiple sclerosis.
    Lulu S; Graves J; Waubant E
    Mult Scler; 2016 Feb; 22(2):193-200. PubMed ID: 25948626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
    Baumstarck K; Pelletier J; Boucekine M; Auquier P;
    Rev Neurol (Paris); 2015 Feb; 171(2):173-80. PubMed ID: 25558798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of relapse phenotype recurrence in multiple sclerosis.
    Kalincik T; Buzzard K; Jokubaitis V; Trojano M; Duquette P; Izquierdo G; Girard M; Lugaresi A; Grammond P; Grand'Maison F; Oreja-Guevara C; Boz C; Hupperts R; Petersen T; Giuliani G; Iuliano G; Lechner-Scott J; Barnett M; Bergamaschi R; Van Pesch V; Amato MP; van Munster E; Fernandez-Bolanos R; Verheul F; Fiol M; Cristiano E; Slee M; Rio ME; Spitaleri D; Alroughani R; Gray O; Saladino ML; Flechter S; Herbert J; Cabrera-Gomez JA; Vella N; Paine M; Shaw C; Moore F; Vucic S; Savino A; Singhal B; Petkovska-Boskova T; Parratt J; Sirbu CA; Rozsa C; Liew D; Butzkueven H;
    Mult Scler; 2014 Oct; 20(11):1511-22. PubMed ID: 24777276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endovascular treatment of chronic cerebrospinal venous insufficiency in multiple sclerosis: a retrospective study.
    Alroughani R; Lamdhade S; Thussu A
    Int J Neurosci; 2013 May; 123(5):324-8. PubMed ID: 23301864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study.
    Salemi G; Callari G; Gammino M; Battaglieri F; Cammarata E; Cuccia G; D'Amelio M; Lupo I; Ragonese P; Savettieri G
    Acta Neurol Scand; 2004 Jul; 110(1):23-6. PubMed ID: 15180803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
    Stellmann JP; Neuhaus A; Herich L; Schippling S; Roeckel M; Daumer M; Martin R; Heesen C
    PLoS One; 2012; 7(11):e50347. PubMed ID: 23209717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.
    Steinvorth SM; Röver C; Schneider S; Nicholas R; Straube S; Friede T
    Mult Scler; 2013 Oct; 19(12):1580-6. PubMed ID: 23471144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
    Baumstarck K; Pelletier J; Butzkueven H; Fernández O; Flachenecker P; Idiman E; Stecchi S; Boucekine M; Auquier P;
    Eur J Neurol; 2013 Jun; 20(6):907-14, e78-9. PubMed ID: 23347258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
    Hartung HP; Kappos L; Goodin DS; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Petkau J; White R; Bogumil T; Beckmann K; Stemper B; Suarez G; Sandbrink R; Pohl C
    J Neurol; 2015 Nov; 262(11):2466-71. PubMed ID: 26239222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.